* AxoGen Inc reported quarterly adjusted earnings of 7 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of 1 cents. The mean expectation of six analysts for the quarter was for earnings of one cent per share. Wall Street expected results to range from -3 cents to 4 cents per share.
* Revenue rose 17.9% to $48.64 million from a year ago; analysts expected $47.07 million.
* AxoGen Inc's reported EPS for the quarter was a loss of 4 cents.
* The company reported a quarterly loss of $1.86 million.
* AxoGen Inc shares had risen by 9.3% this quarter and gained 124.5% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by about 333.3% in the last three months.
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"
Wall Street's median 12-month price target for AxoGen Inc is $17.00 This summary was machine generated from LSEG data November 7 at 02:32 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 0.01 0.07 Beat
Jun. 30 2024 -0.04 0.05 Beat
Mar. 31 2024 -0.07 -0.06 Beat
Dec. 31 2023 -0.10 -0.06 Beat